Artificial intelligence has crossed a new threshold in biology, helping design viruses that can seek out and kill drug resistant bacteria such as dangerous strains of E. coli. Instead of discovering ...

It is a great pleasure to announce that Professor Robert T. Schooley, from the University of California, San Diego (USA), will be a keynote speaker at the 8th World Congress on Targeting Phage Therapy ...

Imagine that the next time you catch a stomach bug and antibiotics fail to work, you knock back a vial of clear liquid. The solution teems with bacteriophages, viruses resembling tiny rocket ships.

In the weightless void of the International Space Station, viruses underwent a transformation that could redefine the fight ...

Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011 ...

BiomX initiates Phase 2b trial for BX004, targeting antibiotic-resistant lung infections in cystic fibrosis patients; results expected Q1 2026. BiomX Inc. has initiated patient dosing in its Phase 2b ...

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...

Collateral damage to normal microbiota, which can be associated with the use of less-specific chemical antibacterials, [4] is avoided. Nonetheless, there are several challenges that must be addressed ...